Medicaid Provider SpendingClaims paid 2018–2024 · HHS public file
Home › CA › West Hills › NPI 1366479099
Lab

Unilab Corporation

Unilab Corporation was paid $668.50M by Medicaid between Jan 2018 and Dec 2024, across 708 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 8.6% of everything it billed.

33Billing provider infoUNILAB CORPORATION
WEST HILLS, CA 91304
33aNPI1366479099assigned 06/27/2006
33bProvider typeClinical Medical Laboratory
28Total paid$668.50M
24GClaims111,637,602
24DCodes billed708
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers

Next to other Clinical Medical Laboratory providers in California

Rank by total paid#1 of 561
Median peer was paid$222K
This provider vs. median3,012×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Auditor's notes

Automated statistical signals. Not evidence of fraud — how these are computed.

Entity ProliferationAuthorized official TIMMERMAN, LEAH controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service

Paid by month

$0$5.0M$10M$15M2018201920202021202220232024
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
YearClaimsPaid
201810,922,838$80.00M
201913,266,254$79.32M
202012,373,965$93.81M
202116,264,901$121.88M
202217,151,409$118.56M
202319,794,120$83.73M
2024incomplete21,864,115$91.20M
Box 24 · Service lines

What it billed for

CodeServiceShareClaimsBene. recordsPaid
U0003 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r 8.6% 1,017,350 936,414 $57.23M
87491 Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe 5.5% 3,367,029 3,247,147 $36.80M
87591 Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe 5.4% 3,348,753 3,229,158 $35.89M
80061 Lipid panel 5.2% 6,916,945 6,846,533 $34.47M
84443 Thyroid stimulating hormone (TSH) 4.5% 5,406,712 5,321,986 $30.19M
80053 Comprehensive metabolic panel 4.3% 8,400,110 8,081,273 $28.98M
82306 Vitamin D; 25 hydroxy, includes fraction(s), if performed 4.2% 2,991,534 2,956,942 $27.77M
83036 Hemoglobin; glycosylated (A1C) 3.0% 6,224,992 6,149,922 $19.77M
85025 Blood count; complete (CBC), automated, and automated differential WBC count 2.4% 7,100,438 6,789,510 $16.25M
88175 Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer 2.1% 1,381,638 1,358,545 $14.25M
80307 Drug test(s), presumptive, any number of drug classes; immunoassay 2.1% 630,793 574,807 $13.84M
87624 Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types 1.9% 1,047,749 1,023,691 $12.97M
696 more codes
87389 Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies 1.9% 2,124,278 $12.89M
86480 1.9% 714,970 $12.37M
86003 1.8% 260,661 $12.10M
80081 1.7% 320,884 $11.57M
81220 CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants 1.6% 114,285 $10.38M
88305 Level IV - Surgical pathology, gross and microscopic examination 1.3% 340,929 $8.46M
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed 1.0% 249,868 $6.96M
87661 Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe 1.0% 549,993 $6.94M
84439 <1% 1,483,913 $6.56M
86803 <1% 1,462,724 $6.42M
81513 <1% 168,786 $6.39M
81420 Fetal chromosomal aneuploidy genomic sequence analysis panel <1% 20,523 $6.29M
80074 <1% 376,616 $6.01M
87799 <1% 270,116 $5.90M
87086 Culture, bacterial; quantitative colony count, urine <1% 1,946,322 $5.66M
87801 Infectious agent detection by nucleic acid; amplified probe, multiple organisms <1% 274,102 $5.60M
86592 <1% 2,775,854 $5.08M
82607 <1% 1,042,557 $4.06M
87536 <1% 171,767 $3.97M
87088 <1% 1,473,352 $3.90M
84153 <1% 650,905 $3.81M
82728 <1% 883,433 $3.70M
82652 <1% 304,811 $3.68M
81162 <1% 4,254 $3.61M
82746 <1% 775,873 $3.60M
36415 Collection of venous blood by venipuncture <1% 4,595,759 $3.58M
81001 <1% 3,116,843 $3.33M
85027 <1% 1,637,348 $3.31M
83013 <1% 207,990 $3.27M
82043 <1% 1,546,453 $3.24M
82570 <1% 1,728,305 $3.13M
87522 Neg quan hep c or qual rna <1% 155,306 $3.09M
86235 <1% 149,300 $2.96M
82274 <1% 606,079 $2.85M
84403 <1% 347,657 $2.85M
87636 Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B <1% 31,799 $2.72M
84481 <1% 356,599 $2.65M
83970 <1% 225,030 $2.56M
87340 <1% 835,805 $2.51M
U0005 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 <1% 177,074 $2.42M
83655 <1% 559,638 $2.32M
86038 <1% 488,155 $2.19M
81329 <1% 50,157 $2.16M
87902 <1% 24,739 $2.02M
84702 <1% 340,201 $2.02M
82670 <1% 197,492 $1.90M
87512 <1% 130,166 $1.84M
G0482 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed <1% 40,426 $1.80M
83550 <1% 806,217 $1.80M
86769 <1% 58,883 $1.71M
87186 <1% 508,380 $1.60M
83540 <1% 924,293 $1.58M
86704 <1% 499,017 $1.57M
84480 <1% 235,316 $1.56M
88142 <1% 203,031 $1.55M
80048 Basic metabolic panel (calcium, ionized) <1% 607,672 $1.52M
83001 <1% 266,166 $1.50M
87635 Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe <1% 42,528 $1.50M
81003 <1% 361,104 $1.46M
86696 <1% 171,398 $1.34M
80050 General health panel <1% 311,321 $1.32M
86708 <1% 397,683 $1.32M
84402 <1% 157,617 $1.28M
86706 <1% 456,767 $1.27M
87077 <1% 502,851 $1.24M
87070 <1% 355,304 $1.21M
86376 <1% 220,425 $1.19M
82105 <1% 109,559 $1.19M
86140 <1% 628,990 $1.18M
86787 <1% 224,079 $1.16M
83880 <1% 112,853 $1.16M
83002 <1% 209,833 $1.16M
87481 <1% 109,029 $1.15M
84146 <1% 204,196 $1.14M
82785 <1% 213,572 $1.13M
84436 <1% 523,384 $1.13M
84550 <1% 648,664 $1.11M
87081 <1% 342,473 $1.08M
85652 <1% 833,339 $1.07M
86317 <1% 275,803 $1.07M
83735 <1% 427,739 $1.01M
86300 <1% 80,427 $971K
88141 <1% 197,012 $969K
86780 <1% 219,772 $933K
86160 <1% 126,056 $916K
87209 <1% 108,227 $909K
86695 <1% 161,334 $872K
88185 <1% 10,452 $857K
87901 <1% 9,399 $843K
83520 <1% 133,662 $838K
85730 <1% 438,203 $828K
86762 <1% 165,472 $825K
87255 <1% 49,109 $812K
85610 <1% 598,980 $804K
82627 <1% 94,986 $786K
87517 <1% 53,985 $762K
86800 <1% 119,436 $757K
87338 <1% 178,631 $730K
83516 <1% 112,926 $729K
84479 <1% 328,340 $725K
82378 <1% 120,512 $724K
82951 <1% 135,149 $681K
86431 <1% 356,466 $668K
84144 <1% 83,598 $666K
82784 <1% 146,250 $661K
G0481 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed <1% 19,428 $661K
82950 <1% 314,802 $630K
86200 <1% 187,053 $617K
80076 <1% 261,933 $610K
G0483 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed <1% 13,682 $596K
86225 <1% 148,562 $590K
87660 <1% 95,000 $579K
84445 <1% 36,108 $570K
86360 <1% 42,692 $567K
86361 <1% 91,509 $556K
99001 <1% 120,866 $552K
80197 <1% 88,281 $547K
81229 <1% 3,408 $541K
87510 <1% 95,456 $541K
86147 <1% 42,664 $536K
87480 <1% 95,441 $536K
86364 <1% 48,399 $534K
86008 <1% 24,385 $503K
86765 <1% 112,778 $501K
87631 <1% 9,813 $498K
86146 <1% 30,674 $496K
81596 <1% 32,126 $487K
84154 <1% 103,429 $479K
86039 <1% 165,409 $464K
80055 <1% 27,937 $463K
82248 <1% 355,273 $457K
87177 <1% 108,616 $450K
83525 <1% 122,308 $448K
86735 <1% 104,382 $437K
87900 <1% 9,396 $432K
84100 <1% 291,605 $428K
82533 <1% 58,976 $401K
83690 <1% 166,122 $392K
88341 <1% 9,923 $391K
86304 <1% 54,709 $384K
87633 Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets <1% 4,161 $381K
88112 <1% 26,016 $379K
84681 <1% 46,609 $362K
83615 <1% 165,983 $361K
82947 <1% 218,510 $360K
86255 <1% 60,851 $359K
84156 <1% 239,415 $349K
84270 <1% 54,894 $349K
88342 <1% 17,800 $348K
87497 <1% 18,300 $345K
87529 <1% 17,353 $339K
88230 <1% 7,174 $335K
87147 <1% 193,658 $331K
86334 <1% 43,343 $325K
88262 <1% 6,892 $323K
82550 <1% 172,173 $321K
83993 <1% 36,249 $319K
88304 <1% 27,606 $317K
83498 <1% 37,992 $309K
88312 <1% 19,500 $308K
86665 <1% 25,639 $307K
84425 <1% 51,834 $297K
80164 <1% 51,006 $297K
81243 <1% 22,072 $289K
87535 <1% 16,526 $289K
88307 <1% 4,219 $287K
86635 <1% 22,983 $282K
82977 <1% 143,269 $279K
81432 <1% 1,253 $275K
80069 <1% 111,177 $271K
87427 <1% 62,935 $270K
87906 <1% 5,293 $265K
82024 <1% 20,876 $263K
83521 <1% 18,538 $262K
84165 <1% 74,094 $257K
86141 <1% 70,056 $254K
0241U Neonatal screening for hereditary disorders, genomic sequence analysis panel <1% 2,908 $252K
82107 <1% 23,768 $252K
82150 <1% 99,450 $251K
83090 <1% 50,615 $249K
81206 <1% 6,659 $247K
84460 <1% 214,297 $233K
84305 <1% 24,557 $233K
83020 <1% 69,424 $233K
86301 <1% 40,349 $228K
86593 <1% 155,791 $222K
82672 <1% 26,557 $220K
83021 <1% 39,205 $219K
81257 <1% 6,162 $218K
87798 Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism <1% 22,275 $218K
84207 <1% 32,828 $213K
86709 <1% 47,773 $212K
87045 <1% 67,090 $210K
87449 <1% 49,627 $210K
81270 <1% 7,026 $209K
83921 <1% 39,824 $207K
86341 <1% 16,036 $197K
86021 <1% 31,644 $196K
86812 <1% 31,099 $193K
84450 <1% 168,246 $191K
87625 <1% 26,967 $191K
87075 <1% 50,257 $190K
83014 <1% 82,313 $184K
82542 <1% 25,956 $181K
86359 <1% 14,308 $178K
84432 <1% 26,936 $178K
86162 <1% 16,418 $174K
82247 <1% 80,083 $170K
87637 Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV <1% 1,910 $166K
85045 <1% 102,699 $162K
81381 <1% 4,030 $161K
82565 <1% 115,448 $159K
86705 <1% 35,549 $156K
85379 <1% 27,496 $154K
86901 <1% 118,316 $154K
82088 <1% 11,920 $152K
82465 <1% 88,779 $149K
84134 <1% 21,143 $148K
84703 <1% 68,563 $147K
86900 <1% 113,456 $144K
84478 <1% 54,797 $142K
83718 <1% 36,232 $140K
82140 <1% 23,332 $136K
85060 <1% 38,546 $132K
86850 <1% 81,367 $130K
88189 <1% 9,119 $130K
86381 <1% 18,470 $129K
82668 <1% 16,981 $124K
85613 <1% 34,276 $121K
82330 <1% 32,115 $121K
82157 <1% 9,821 $118K
85018 <1% 168,616 $117K
83883 <1% 19,700 $116K
83721 <1% 72,785 $116K
87205 <1% 62,486 $115K
81025 <1% 35,500 $115K
86015 <1% 21,491 $114K
82952 <1% 70,686 $114K
84630 <1% 30,161 $113K
86664 <1% 19,650 $112K
88360 <1% 2,510 $112K
87563 <1% 10,650 $112K
88184 <1% 10,422 $111K
86870 <1% 10,837 $110K
81219 <1% 3,581 $110K
88173 <1% 4,517 $109K
80177 <1% 19,978 $109K
87506 <1% 1,121 $107K
85246 <1% 11,290 $107K
87329 <1% 30,828 $106K
85240 <1% 11,840 $103K
87324 <1% 21,000 $103K
84244 <1% 12,232 $102K
83519 <1% 12,097 $102K
80361 <1% 27,065 $101K
86481 <1% 4,198 $100K
82653 <1% 5,179 $99K
83010 <1% 17,668 $98K
87046 <1% 36,932 $98K
82626 <1% 9,852 $96K
81207 <1% 3,862 $96K
86682 <1% 13,346 $93K
84482 <1% 6,524 $93K
81279 <1% 2,966 $92K
80178 <1% 31,824 $92K
82390 <1% 23,867 $90K
84166 <1% 15,811 $88K
81401 <1% 1,766 $88K
84182 <1% 4,135 $88K
85245 <1% 9,582 $87K
81479 Unlisted molecular pathology procedure <1% 3,849 $86K
82172 <1% 21,485 $85K
84466 <1% 25,799 $85K
80159 <1% 14,112 $84K
86702 <1% 16,198 $84K
82310 <1% 68,594 $82K
83835 <1% 8,395 $82K
85014 <1% 103,553 $82K
80349 <1% 20,068 $82K
99199 Unlisted special service, procedure or report <1% 94,333 $79K
86036 <1% 15,408 $78K
82232 <1% 11,883 $77K
87350 <1% 22,593 $77K
86644 <1% 12,814 $76K
81241 <1% 5,038 $74K
87999 <1% 1,829 $74K
86258 <1% 5,271 $74K
86355 <1% 6,140 $74K
82397 <1% 7,382 $73K
82103 <1% 14,036 $73K
82530 <1% 9,087 $72K
86337 <1% 7,534 $71K
81339 <1% 2,721 $71K
83951 <1% 5,027 $71K
85007 <1% 78,142 $70K
85247 <1% 6,101 $68K
82525 <1% 18,912 $67K
86645 <1% 9,621 $67K
81403 <1% 1,251 $67K
82787 <1% 5,920 $66K
86777 <1% 11,515 $65K
87493 <1% 6,124 $65K
80202 <1% 10,131 $63K
81433 <1% 746 $63K
84520 <1% 63,472 $63K
86701 <1% 17,068 $62K
83704 <1% 8,542 $62K
82040 <1% 45,518 $61K
86618 <1% 8,179 $58K
80299 <1% 8,629 $57K
81364 <1% 709 $56K
81382 <1% 1,080 $55K
81256 <1% 2,357 $54K
84590 <1% 16,991 $52K
82085 <1% 23,917 $52K
80158 <1% 4,347 $52K
80156 <1% 8,937 $52K
80175 <1% 7,541 $52K
87101 <1% 16,813 $52K
86335 <1% 6,688 $51K
86357 <1% 4,101 $51K
83695 <1% 16,149 $51K
86707 <1% 19,604 $50K
84155 <1% 48,101 $50K
G0328 Colorectal cancer screening; fecal occult blood test, immunoassay, 1-3 simultaneous <1% 12,840 $49K
82610 <1% 8,788 $48K
84484 <1% 8,240 $48K
82239 <1% 6,490 $47K
86790 <1% 3,917 $47K
87210 <1% 61,689 $47K
85306 <1% 6,592 $47K
80185 <1% 8,067 $46K
81240 <1% 3,789 $46K
87076 <1% 15,044 $45K
0001M <1% 1,138 $45K
80373 <1% 17,118 $45K
88271 <1% 1,231 $44K
82985 <1% 6,353 $44K
86060 <1% 15,898 $43K
86001 <1% 4,188 $43K
86617 <1% 3,488 $42K
86671 <1% 8,683 $42K
86778 <1% 6,893 $41K
85041 <1% 50,764 $40K
84075 <1% 30,952 $40K
81015 <1% 70,101 $39K
82384 <1% 3,703 $39K
85303 <1% 6,592 $39K
87150 <1% 4,717 $39K
86148 <1% 4,368 $38K
82507 <1% 4,853 $38K
85300 <1% 5,286 $38K
80051 <1% 23,304 $38K
80346 <1% 12,041 $37K
87102 <1% 10,169 $37K
85384 <1% 8,623 $37K
83698 <1% 3,906 $36K
80365 <1% 22,553 $35K
82681 <1% 3,483 $35K
82747 <1% 9,157 $34K
87040 <1% 6,588 $34K
84255 <1% 3,350 $33K
87521 Neg quan hep c or qual rna <1% 1,689 $33K
87502 Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets <1% 1,379 $33K
84132 <1% 23,352 $33K
87467 <1% 2,794 $30K
80321 <1% 10,680 $30K
82164 <1% 7,617 $29K
80195 <1% 4,119 $29K
86382 <1% 2,187 $29K
87206 <1% 14,209 $28K
84446 <1% 10,469 $28K
81376 <1% 1,035 $27K
86308 <1% 13,487 $27K
82552 <1% 3,474 $27K
89055 <1% 14,515 $27K
86774 <1% 5,433 $26K
87662 <1% 635 $26K
85598 <1% 4,421 $26K
85597 <1% 4,709 $26K
83825 <1% 3,941 $25K
80348 <1% 15,460 $25K
81402 <1% 668 $24K
G0472 Hepatitis c antibody screening, for individual at high risk and other covered indication(s) <1% 4,558 $24K
82104 <1% 6,539 $24K
G0103 Prostate cancer screening; prostate specific antigen test (psa) <1% 6,551 $24K
83935 <1% 7,438 $24K
82175 <1% 3,104 $23K
88275 <1% 687 $23K
86231 <1% 3,355 $23K
84080 <1% 4,310 $23K
86316 <1% 3,553 $23K
87220 <1% 12,205 $23K
80323 <1% 8,700 $22K
83874 <1% 910 $22K
82166 <1% 3,748 $22K
86747 <1% 2,500 $22K
82705 <1% 6,873 $22K
82308 <1% 1,420 $21K
84300 <1% 13,207 $21K
G0145 Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision <1% 4,594 $20K
82523 <1% 2,592 $20K
87116 <1% 6,162 $19K
86256 <1% 4,812 $19K
83003 <1% 3,327 $19K
87632 <1% 155 $19K
81374 <1% 1,618 $19K
80368 <1% 9,573 $19K
88313 <1% 1,167 $18K
82955 <1% 5,690 $18K
86648 <1% 4,179 $18K
80183 <1% 2,503 $18K
84597 <1% 4,549 $18K
80184 <1% 3,127 $18K
83945 <1% 4,958 $18K
80162 <1% 3,908 $18K
82679 <1% 1,835 $17K
87230 <1% 2,712 $17K
82379 <1% 1,375 $17K
84295 <1% 15,079 $17K
84252 <1% 3,685 $17K
83930 <1% 6,013 $17K
81517 <1% 489 $16K
82642 <1% 1,813 $16K
82340 <1% 9,125 $16K
84140 <1% 2,343 $16K
85660 <1% 15,703 $16K
82139 <1% 588 $16K
87107 <1% 4,338 $16K
88302 <1% 559 $16K
86037 <1% 2,638 $16K
87912 <1% 1,186 $15K
82575 <1% 4,396 $15K
87634 <1% 1,054 $15K
87140 <1% 5,398 $15K
80324 <1% 7,432 $15K
85048 <1% 20,305 $15K
85305 <1% 2,792 $15K
82671 <1% 588 $15K
83630 <1% 1,158 $15K
36416 <1% 3,557 $14K
80369 <1% 5,411 $14K
87106 <1% 4,573 $14K
84376 <1% 2,423 $14K
80165 <1% 2,233 $14K
80372 <1% 10,915 $14K
82656 <1% 827 $14K
80354 <1% 20,137 $14K
82365 <1% 3,073 $13K
87880 Infectious agent antigen detection by immunoassay; Streptococcus, group A <1% 2,158 $13K
86340 <1% 2,322 $13K
U0002 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc <1% 315 $13K
86403 <1% 3,128 $12K
87015 <1% 6,605 $12K
88237 <1% 279 $12K
84591 <1% 2,469 $12K
85004 <1% 8,270 $12K
80320 <1% 7,176 $12K
80358 <1% 9,174 $12K
86606 <1% 1,127 $11K
80362 <1% 5,651 $11K
86663 <1% 1,865 $11K
80201 <1% 2,176 $11K
81291 <1% 2,256 $11K
82435 <1% 10,972 $11K
87425 <1% 318 $11K
82180 <1% 5,195 $11K
82553 <1% 2,817 $11K
86880 <1% 6,014 $11K
87254 <1% 1,585 $11K
84238 <1% 489 $10K
88264 <1% 278 $10K
80353 <1% 4,342 $10K
88377 <1% 228 $10K
86615 <1% 1,561 $10K
83992 <1% 7,202 $10K
80337 <1% 6,373 $10K
81332 <1% 923 $9K
87850 <1% 1,508 $9K
80370 <1% 6,353 $9K
85302 <1% 2,097 $9K
80360 <1% 4,770 $9K
80326 <1% 6,351 $9K
80355 <1% 6,030 $9K
85301 <1% 2,099 $9K
87804 Infectious agent antigen detection by immunoassay; Influenza, each type <1% 868 $9K
83605 <1% 2,018 $9K
80338 <1% 6,497 $8K
80503 <1% 1,997 $8K
86692 <1% 2,024 $8K
84560 <1% 6,016 $8K
84133 <1% 6,375 $8K
84145 <1% 750 $8K
87328 <1% 2,298 $7K
83527 <1% 724 $7K
G0475 Hiv antigen/antibody, combination assay, screening <1% 2,081 $7K
80366 <1% 5,020 $7K
80377 <1% 6,348 $7K
84105 <1% 4,943 $7K
80345 <1% 7,638 $7K
80359 <1% 3,129 $7K
82595 <1% 3,815 $7K
80356 <1% 5,604 $7K
82657 <1% 566 $6K
87185 <1% 5,490 $6K
86343 <1% 1,839 $6K
88344 <1% 82 $6K
80364 <1% 2,994 $6K
84378 <1% 1,608 $6K
86041 <1% 410 $6K
86905 <1% 3,487 $6K
86886 <1% 3,414 $6K
86611 <1% 1,000 $6K
80367 <1% 3,493 $5K
86161 <1% 917 $5K
84392 <1% 4,021 $5K
83986 <1% 4,799 $5K
80235 <1% 1,063 $5K
82941 <1% 709 $5K
86794 <1% 528 $5K
80344 <1% 2,082 $5K
81335 <1% 127 $5K
99058 <1% 12,294 $5K
80340 <1% 2,095 $5K
85049 <1% 4,729 $4K
87272 <1% 1,439 $4K
80333 <1% 2,095 $4K
80342 <1% 4,279 $4K
99000 <1% 574 $4K
86631 <1% 513 $4K
P9011 Blood, split unit <1% 1,521 $4K
80363 <1% 4,097 $3K
80357 <1% 2,257 $3K
84433 <1% 156 $3K
87650 <1% 663 $3K
80339 <1% 4,030 $3K
89060 <1% 2,272 $3K
82731 <1% 195 $3K
85670 <1% 1,308 $3K
86043 <1% 184 $3K
80167 <1% 137 $3K
87341 <1% 1,381 $3K
82374 <1% 6,141 $3K
86698 <1% 391 $3K
80332 <1% 4,245 $3K
87593 <1% 612 $3K
84311 <1% 247 $3K
87110 <1% 153 $3K
86738 <1% 376 $3K
82540 <1% 2,405 $3K
81443 <1% 127 $3K
84143 <1% 578 $3K
86632 <1% 540 $2K
86042 <1% 189 $2K
80371 <1% 2,272 $2K
83625 <1% 923 $2K
80330 <1% 2,092 $2K
89051 <1% 2,428 $2K
80329 <1% 4,310 $2K
80335 <1% 944 $2K
81301 <1% 53 $2K
89321 <1% 573 $2K
80203 <1% 203 $2K
83497 <1% 321 $2K
0346U <1% 159 $2K
84585 <1% 311 $2K
81327 <1% 2,209 $2K
83631 <1% 396 $1K
86703 <1% 272 $1K
88289 <1% 168 $1K
80180 <1% 118 $1K
83018 <1% 141 $1K
85999 <1% 316 $1K
80325 <1% 119 $1K
86305 <1% 433 $1K
87207 <1% 425 $1K
87149 <1% 31 $1K
80169 <1% 211 $1K
86609 <1% 275 $1K
84206 <1% 96 $1K
86710 <1% 143 $972.22
81225 <1% 145 $955.29
85307 <1% 179 $935.47
87276 <1% 415 $915.28
87275 <1% 415 $910.58
87807 <1% 478 $857.86
0014M <1% 26 $817.52
88187 <1% 138 $787.67
86336 <1% 243 $753.57
88300 <1% 295 $734.16
84442 <1% 298 $635.47
87280 <1% 275 $635.12
82978 <1% 55 $621.46
85810 <1% 227 $572.05
87109 <1% 309 $543.93
88321 <1% 53 $532.04
84260 <1% 72 $467.55
85385 <1% 80 $417.79
83937 <1% 91 $413.30
80374 <1% 3,453 $391.16
82608 <1% 100 $385.33
86596 <1% 13 $381.84
80375 <1% 992 $376.04
86023 <1% 121 $360.30
87172 <1% 174 $351.13
80500 <1% 820 $326.33
86628 <1% 39 $319.54
86332 <1% 607 $311.20
G0123 Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision <1% 164 $304.30
87530 <1% 190 $292.78
82436 <1% 135 $278.75
84588 <1% 14 $278.10
87118 <1% 153 $264.97
87556 <1% 55 $256.40
87305 <1% 119 $237.97
87279 <1% 27 $233.22
85651 <1% 235 $216.80
82710 <1% 38 $211.48
86215 <1% 29 $209.86
G0476 Infectious agent detection by nucleic acid (dna or rna); human papillomavirus (hpv), high-risk types (e.g., 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68) for cervical cancer screening, must be performed in addition to pap test <1% 77 $185.42
80352 <1% 860 $184.61
86753 <1% 30 $176.16
87300 <1% 187 $170.08
89320 <1% 116 $166.19
86788 <1% 24 $141.90
82300 <1% 38 $137.11
80204 <1% 18 $108.00
86052 <1% 53 $107.13
84181 <1% 25 $102.18
85362 <1% 70 $97.93
87260 <1% 27 $91.82
86022 <1% 12 $87.26
82677 <1% 26 $86.78
80186 <1% 25 $86.42
87496 <1% 12 $82.93
83918 <1% 12 $82.72
80168 <1% 12 $78.71
87385 <1% 18 $68.69
87503 <1% 31 $67.14
88311 <1% 13 $64.04
85250 <1% 16 $50.30
86789 <1% 12 $38.11
84540 <1% 25 $32.20
85420 <1% 14 $30.80
86331 <1% 14 $23.96
80171 <1% 64 $23.17
87184 <1% 26 $21.15
85244 <1% 18 $18.98
88164 <1% 25 $16.59
G0306 Complete cbc, automated (hgb, hct, rbc, wbc, without platelet count) and automated wbc differential count <1% 76 $4.62
99283 Emergency room visit (moderate) 0% 120 $0.00
99213 Doctor's office visit, returning patient (routine) 0% 1,270 $0.00
3044F 0% 63,707 $0.00
3048F 0% 9,508 $0.00
3049F 0% 5,905 $0.00
84431 0% 397 $0.00
3052F 0% 3,623 $0.00
H0049 Alcohol and/or drug screening 0% 61 $0.00
81255 0% 56 $0.00
81200 0% 39 $0.00
92004 Ophthalmological services: medical examination and evaluation, comprehensive, new patient 0% 13 $0.00
89322 0% 12 $0.00
3351F 0% 84 $0.00
90471 Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine 0% 13 $0.00
E0431 Portable gaseous oxygen system, rental; includes portable container, regulator, flowmeter, humidifier, cannula or mask, and tubing 0% 12 $0.00
99214 Doctor's office visit, returning patient (more involved) 0% 86 $0.00
83789 0% 703 $0.00
H2019 Therapeutic behavioral services, billed per 15 minutes 0% 100 $0.00
95117 0% 23 $0.00
99285 Emergency room visit (most serious) 0% 14 $0.00
81000 0% 13 $0.00
T4535 Disposable liner/shield/guard/pad/undergarment, for incontinence, each 0% 13 $0.00
3008F 0% 25 $0.00
92014 Ophthalmological services: medical examination and evaluation, comprehensive, established patient 0% 40 $0.00
3050F 0% 4,251 $0.00
88120 0% 12 $0.00
3051F 0% 5,763 $0.00
92015 Determination of refractive state 0% 113 $0.00
99284 Emergency room visit (serious) 0% 19 $0.00
3046F 0% 5,560 $0.00
92340 Fitting of spectacles, except for aphakia; monofocal 0% 30 $0.00
T4541 Incontinence product, disposable underpad, large, each 0% 51 $0.00
T1015 A visit at a community health center or clinic (one all-in rate) 0% 112 $0.00
V2020 Frames, purchases 0% 30 $0.00
P9604 Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge 0% 94 $0.00
97039 0% 32 $0.00
T4526 Adult sized disposable incontinence product, protective underwear/pull-on, medium size, each 0% 14 $0.00
S5111 Home care training, family; per session 0% 65 $0.00
3725F 0% 62 $0.00
88147 0% 15 $0.00
H0046 Mental health services, not otherwise specified 0% 57 $0.00
81260 0% 40 $0.00
99212 Office or other outpatient visit for the evaluation and management of an established patient, straightforward 0% 41 $0.00
S9999 Sales tax 0% 30 $0.00
T4527 Adult sized disposable incontinence product, protective underwear/pull-on, large size, each 0% 15 $0.00
A0425 Ground mileage, per statute mile 0% 15 $0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialTIMMERMAN, LEAH (VICE PRESIDENT)
Parent organizationQUEST DIAGNOSTICS INCORPORATED
Same official

Other billing entities under TIMMERMAN, LEAH

Full network →
ProviderLocationPaid
Quest Diagnostics IncorporatedClifton, NJ$637.74M
Quest Diagnostics LLC IlWood Dale, IL$429.84M
Quest Diagnostics Clinical Laboratories INCIrving, TX$276.76M
Labone LLCLenexa, KS$212.28M
Quest Diagnostics Clinical Laboratories INCTucker, GA$211.13M
Quest Diagnostics Clinical Laboratories INCMiramar, FL$197.58M
Labone of Ohio INCCincinnati, OH$167.17M
Unilab CorporationSacramento, CA$141.24M
Quest Diagnostics Incorporated MDBaltimore, MD$121.81M
Quest Diagnostics IncorporatedLas Vegas, NV$59.32M
Quest Diagnostics LLC IlSchaumburg, IL$50.71M
Quest Diagnostics Clinical Laboratories INCTampa, FL$49.99M
Quest Diagnostics Nichols Institute, INC.Chantilly, VA$46.91M
Quest Diagnostics Nichols InstituteSan Juan Capistrano, CA$39.93M
Quest Diagnostics Clinical Laboratories INCNorristown, PA$22.72M
Specialty Laboratories INCWest Hills, CA$16.76M
Quest Diagnostics Clinical Laboratories INCDenver, CO$14.27M
Quest Diagnostics Clinical Laboratories INCHouston, TX$8.76M
Med Fusion, LLCLewisville, TX$4.17M
Quest Diagnostics Clinical Laboratories INCMaryland Heights, MO$2.98M

Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.